kynurenine has been researched along with Acute Confusional Senile Dementia in 50 studies
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, other pathophysiological features of the disease have emerged including neuroinflammation and dysregulation of the kynurenine pathway (KP)." | 9.01 | Microbiota Alterations in Alzheimer's Disease: Involvement of the Kynurenine Pathway and Inflammation. ( Garcez, ML; Guillemin, GJ; Jacobs, KR, 2019) |
| "Neurodegenerative diseases (NDs) like Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's disease, and Huntington's disease predominantly pose a significant socioeconomic burden." | 6.72 | Hypoxia and the Kynurenine Pathway: Implications and Therapeutic Prospects in Alzheimer's Disease. ( Adeyemi, OS; Afolabi, LB; Alejolowo, O; Arowolo, AT; Awakan, OJ; Elebiyo, TC; Ibraheem, O; Oluwayemi, E; Otuechere, CA; Rotimi, DE, 2021) |
| "Alzheimer's disease (AD) and Parkinson's disease (PD) are the most common neurodegenerative diseases (NDs), presenting a broad range of symptoms from motor dysfunctions to psychobehavioral manifestations." | 6.66 | Exploring the Etiological Links behind Neurodegenerative Diseases: Inflammatory Cytokines and Bioactive Kynurenines. ( Tanaka, M; Toldi, J; Vécsei, L, 2020) |
| "The pathomechanism of Alzheimer's disease (AD) certainly involves mitochondrial disturbances, glutamate excitotoxicity, and neuroinflammation." | 6.58 | Alzheimer's Disease: Recent Concepts on the Relation of Mitochondrial Disturbances, Excitotoxicity, Neuroinflammation, and Kynurenines. ( Klivényi, P; Szalárdy, L; Vécsei, L; Veres, G; Zádori, D, 2018) |
| "In 58 cognitively normal, 396 mild cognitive impairment, and 112 AD participants from the Alzheimer's Disease Neuroimaging Initiative-1 (ADNI1) cohort, serum markers of 5-HT, tryptophan, and Kyn were measured and their relationships investigated with immunologic markers, affect and functional outcomes, CSF markers of beta-amyloid (Aβ) and tau, and regional gray matter." | 5.62 | Inflammation, negative affect, and amyloid burden in Alzheimer's disease: Insights from the kynurenine pathway. ( Allenspach, K; Collazo-Martinez, AD; Dantzer, R; Hoth, N; Klinedinst, B; Larsen, B; Le, S; Li, T; Mochel, JP; Pappas, C; Pollpeter, A; Wang, Q; Willette, AA; Willette, SA, 2021) |
| " However, other pathophysiological features of the disease have emerged including neuroinflammation and dysregulation of the kynurenine pathway (KP)." | 5.01 | Microbiota Alterations in Alzheimer's Disease: Involvement of the Kynurenine Pathway and Inflammation. ( Garcez, ML; Guillemin, GJ; Jacobs, KR, 2019) |
| " Neuronal EAAT2 deletion leads to dysregulation of the kynurenine pathway, and astrocytic EAAT2 deficiency results in dysfunction of innate and adaptive immune pathways, which correlate with cognitive decline." | 3.91 | Divergent roles of astrocytic versus neuronal EAAT2 deficiency on cognition and overlap with aging and Alzheimer's molecular signatures. ( Gray, JD; Kazim, SF; Larson, CS; McEwen, BS; Pereira, AC; Ramakrishnan, A; Rosenberg, PA; Sharma, A; Shen, L, 2019) |
| " Low xanthurenic acid occurred in both AD and with aging." | 3.85 | Kynurenine Pathway Metabolites in Alzheimer's Disease. ( Advani, R; Giil, LM; Midttun, Ø; Refsum, H; Smith, AD; Ueland, PM; Ulvik, A, 2017) |
| "Boosting KYNA levels, through interference with the KP enzymes or through application of prodrugs/analogs with high bioavailability and potency, is a promising clinical approach." | 2.82 | Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword? ( Ostapiuk, A; Urbanska, EM, 2022) |
| "Neurodegenerative diseases (NDs) like Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's disease, and Huntington's disease predominantly pose a significant socioeconomic burden." | 2.72 | Hypoxia and the Kynurenine Pathway: Implications and Therapeutic Prospects in Alzheimer's Disease. ( Adeyemi, OS; Afolabi, LB; Alejolowo, O; Arowolo, AT; Awakan, OJ; Elebiyo, TC; Ibraheem, O; Oluwayemi, E; Otuechere, CA; Rotimi, DE, 2021) |
| "Alzheimer's disease (AD) and Parkinson's disease (PD) are the most common neurodegenerative diseases (NDs), presenting a broad range of symptoms from motor dysfunctions to psychobehavioral manifestations." | 2.66 | Exploring the Etiological Links behind Neurodegenerative Diseases: Inflammatory Cytokines and Bioactive Kynurenines. ( Tanaka, M; Toldi, J; Vécsei, L, 2020) |
| "The pathomechanism of Alzheimer's disease (AD) certainly involves mitochondrial disturbances, glutamate excitotoxicity, and neuroinflammation." | 2.58 | Alzheimer's Disease: Recent Concepts on the Relation of Mitochondrial Disturbances, Excitotoxicity, Neuroinflammation, and Kynurenines. ( Klivényi, P; Szalárdy, L; Vécsei, L; Veres, G; Zádori, D, 2018) |
| "The kynurenine pathway (KP) has been implicated in the development of neurodegenerative processes, and alterations in the KP have been demonstrated in both acute and chronic neurological disorders." | 2.50 | The potential role of kynurenines in Alzheimer's disease: pathomechanism and therapeutic possibilities by influencing the glutamate receptors. ( Majláth, Z; Toldi, J; Vécsei, L, 2014) |
| "The kynurenine pathway (KP) is a major route of L-tryptophan catabolism leading to production of a number of biologically active molecules." | 2.41 | Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease. ( Brew, BJ; Guillemin, GJ, 2002) |
| "Studies in Alzheimer's disease (AD) patients confirm KP dyshomeostasis in plasma and cerebrospinal fluid (CSF) which correlates with amyloid-β and tau pathology." | 1.72 | Systemic perturbations of the kynurenine pathway precede progression to dementia independently of amyloid-β. ( Bourgeat, P; Cespedes, M; Chatterjee, P; Doecke, JD; Fowler, CJ; Guillemin, GJ; Ittner, A; Jacobs, KR; Lim, CK; Lovejoy, DB; Martins, RN; Maruff, P; Masters, CL; Pertile, KK; Rainey-Smith, SR; Rembach, A; Rowe, CC; Rumble, RL; Trounson, B; Villemagne, VL, 2022) |
| "Urine and serum serotonin concentrations were found to be significantly lower in AD compared with controls, suggesting the bioavailability of the neurotransmitter may be altered in the disease." | 1.62 | Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer's disease. ( Chappell, KE; D'Hondt, E; Holmes, E; Hye, A; Jiménez, B; Kłoszewska, I; Legido-Quigley, C; Lewis, MR; Lovestone, S; Mecocci, P; Snowden, SG; Soininen, H; Swann, JR; Tsolaki, M; Vellas, B; Whiley, L, 2021) |
| "In 58 cognitively normal, 396 mild cognitive impairment, and 112 AD participants from the Alzheimer's Disease Neuroimaging Initiative-1 (ADNI1) cohort, serum markers of 5-HT, tryptophan, and Kyn were measured and their relationships investigated with immunologic markers, affect and functional outcomes, CSF markers of beta-amyloid (Aβ) and tau, and regional gray matter." | 1.62 | Inflammation, negative affect, and amyloid burden in Alzheimer's disease: Insights from the kynurenine pathway. ( Allenspach, K; Collazo-Martinez, AD; Dantzer, R; Hoth, N; Klinedinst, B; Larsen, B; Le, S; Li, T; Mochel, JP; Pappas, C; Pollpeter, A; Wang, Q; Willette, AA; Willette, SA, 2021) |
| "The kynurenine pathway (KP) is a major route of tryptophan metabolism." | 1.36 | Kynurenine and its metabolites in Alzheimer's disease patients. ( Bien, B; Gulaj, E; Pawlak, D; Pawlak, K, 2010) |
| "In the Tg2576 mouse model of Alzheimer's disease, systemic inflammation induced by lipopolysaccharide leads to an increase in IDO expression and QUIN production in microglia surrounding amyloid plaques." | 1.35 | Proinflammatory cytokine interferon-gamma increases induction of indoleamine 2,3-dioxygenase in monocytic cells primed with amyloid beta peptide 1-42: implications for the pathogenesis of Alzheimer's disease. ( Akimoto, H; Guillemin, GJ; Kagawa, S; Takikawa, O; Yamada, A, 2009) |
| "L-kynurenine (L-KYN) serves as a substrate for the synthesis of neurotoxic 3-OH-kynurenine (3-OH-KYN) and neuroprotective kynurenic acid (KYNA)." | 1.30 | Kynurenine metabolism in Alzheimer's disease. ( Baran, H; Deecke, L; Jellinger, K, 1999) |
| "3-Hydroxykynurenine was substantially and significantly increased in all three brain areas studied in Huntington's disease, but not significantly increased in the cortex in Alzheimer's disease, when compared to matched controls." | 1.28 | Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease. ( Pearson, SJ; Reynolds, GP, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (12.00) | 18.2507 |
| 2000's | 7 (14.00) | 29.6817 |
| 2010's | 22 (44.00) | 24.3611 |
| 2020's | 15 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adeyemi, OS | 1 |
| Awakan, OJ | 1 |
| Afolabi, LB | 1 |
| Rotimi, DE | 1 |
| Oluwayemi, E | 1 |
| Otuechere, CA | 1 |
| Ibraheem, O | 1 |
| Elebiyo, TC | 1 |
| Alejolowo, O | 1 |
| Arowolo, AT | 1 |
| Ostapiuk, A | 1 |
| Urbanska, EM | 1 |
| Liang, Y | 1 |
| Xie, S | 1 |
| He, Y | 1 |
| Xu, M | 1 |
| Qiao, X | 1 |
| Zhu, Y | 1 |
| Wu, W | 2 |
| Sharma, VK | 1 |
| Singh, TG | 1 |
| Prabhakar, NK | 1 |
| Mannan, A | 1 |
| Cespedes, M | 1 |
| Jacobs, KR | 5 |
| Maruff, P | 1 |
| Rembach, A | 1 |
| Fowler, CJ | 1 |
| Trounson, B | 1 |
| Pertile, KK | 1 |
| Rumble, RL | 1 |
| Rainey-Smith, SR | 1 |
| Rowe, CC | 1 |
| Villemagne, VL | 1 |
| Bourgeat, P | 1 |
| Lim, CK | 5 |
| Chatterjee, P | 4 |
| Martins, RN | 4 |
| Ittner, A | 1 |
| Masters, CL | 1 |
| Doecke, JD | 1 |
| Guillemin, GJ | 10 |
| Lovejoy, DB | 4 |
| Almulla, AF | 1 |
| Supasitthumrong, T | 1 |
| Amrapala, A | 1 |
| Tunvirachaisakul, C | 1 |
| Jaleel, AKA | 1 |
| Oxenkrug, G | 1 |
| Al-Hakeim, HK | 1 |
| Maes, M | 1 |
| Martins, LB | 1 |
| Silveira, ALM | 1 |
| Teixeira, AL | 1 |
| Fathi, M | 1 |
| Vakili, K | 1 |
| Yaghoobpoor, S | 1 |
| Tavasol, A | 1 |
| Jazi, K | 1 |
| Hajibeygi, R | 1 |
| Shool, S | 1 |
| Sodeifian, F | 1 |
| Klegeris, A | 1 |
| McElhinney, A | 1 |
| Tavirani, MR | 1 |
| Sayehmiri, F | 1 |
| Parker, DC | 1 |
| Kraus, WE | 1 |
| Whitson, HE | 1 |
| Kraus, VB | 1 |
| Smith, PJ | 1 |
| Cohen, HJ | 1 |
| Pieper, CF | 1 |
| Faldowski, RA | 1 |
| Hall, KS | 1 |
| Huebner, JL | 1 |
| Ilkayeva, OR | 1 |
| Bain, JR | 1 |
| Newby, LK | 1 |
| Huffman, KM | 1 |
| Sharma, A | 1 |
| Kazim, SF | 1 |
| Larson, CS | 1 |
| Ramakrishnan, A | 1 |
| Gray, JD | 1 |
| McEwen, BS | 1 |
| Rosenberg, PA | 1 |
| Shen, L | 1 |
| Pereira, AC | 1 |
| Zetterberg, H | 2 |
| Goozee, K | 2 |
| Ashton, NJ | 1 |
| Hye, A | 2 |
| Pedrini, S | 1 |
| Sohrabi, HR | 2 |
| Shah, T | 2 |
| Asih, PR | 2 |
| Dave, P | 2 |
| Shen, K | 2 |
| Taddei, K | 2 |
| Blennow, K | 2 |
| Esmaeili, S | 1 |
| Ghobadi, N | 1 |
| Akbari, V | 1 |
| Moradi, S | 1 |
| Shahlaie, M | 1 |
| Ghobadi, S | 1 |
| Jalalvand, AR | 1 |
| Amani, M | 1 |
| Khodarahmi, R | 1 |
| Tanaka, M | 1 |
| Toldi, J | 5 |
| Vécsei, L | 7 |
| Duan, Z | 1 |
| Zhang, S | 1 |
| Liang, H | 1 |
| Xing, Z | 1 |
| Guo, L | 1 |
| Shi, L | 1 |
| Du, L | 1 |
| Kuang, C | 1 |
| Takikawa, O | 3 |
| Yang, Q | 1 |
| Whiley, L | 1 |
| Chappell, KE | 1 |
| D'Hondt, E | 1 |
| Lewis, MR | 1 |
| Jiménez, B | 1 |
| Snowden, SG | 1 |
| Soininen, H | 1 |
| Kłoszewska, I | 1 |
| Mecocci, P | 1 |
| Tsolaki, M | 1 |
| Vellas, B | 1 |
| Swann, JR | 1 |
| Lovestone, S | 1 |
| Legido-Quigley, C | 1 |
| Holmes, E | 1 |
| Willette, AA | 1 |
| Pappas, C | 1 |
| Hoth, N | 1 |
| Wang, Q | 1 |
| Klinedinst, B | 1 |
| Willette, SA | 1 |
| Larsen, B | 1 |
| Pollpeter, A | 1 |
| Li, T | 1 |
| Le, S | 1 |
| Collazo-Martinez, AD | 1 |
| Mochel, JP | 1 |
| Allenspach, K | 1 |
| Dantzer, R | 1 |
| van der Velpen, V | 1 |
| Rosenberg, N | 1 |
| Maillard, V | 1 |
| Teav, T | 1 |
| Chatton, JY | 1 |
| Gallart-Ayala, H | 1 |
| Ivanisevic, J | 1 |
| Giil, LM | 1 |
| Midttun, Ø | 1 |
| Refsum, H | 1 |
| Ulvik, A | 1 |
| Advani, R | 1 |
| Smith, AD | 1 |
| Ueland, PM | 1 |
| Robertson, DS | 1 |
| Zádori, D | 2 |
| Veres, G | 1 |
| Szalárdy, L | 1 |
| Klivényi, P | 3 |
| James, I | 1 |
| ManYan, C | 1 |
| Chung, R | 2 |
| Sharma, R | 1 |
| Razdan, K | 1 |
| Bansal, Y | 1 |
| Kuhad, A | 1 |
| Brew, BJ | 4 |
| Garcez, ML | 1 |
| Sorgdrager, FJH | 1 |
| Vermeiren, Y | 1 |
| Van Faassen, M | 1 |
| van der Ley, C | 1 |
| Nollen, EAA | 1 |
| Kema, IP | 1 |
| De Deyn, PP | 1 |
| Wissmann, P | 1 |
| Geisler, S | 1 |
| Leblhuber, F | 4 |
| Fuchs, D | 4 |
| Nicolazzo, JA | 1 |
| Wen, L | 1 |
| Stankovic, R | 1 |
| Bao, SS | 1 |
| Cullen, KM | 2 |
| Majláth, Z | 1 |
| Dezsi, L | 1 |
| Tuka, B | 1 |
| Martos, D | 1 |
| Mazarei, G | 1 |
| Leavitt, BR | 1 |
| Rommer, PS | 1 |
| Schroth, R | 1 |
| Greilberger, M | 1 |
| Tafeit, E | 1 |
| Greilberger, J | 1 |
| Vamos, E | 1 |
| Pardutz, A | 1 |
| Yamada, A | 1 |
| Akimoto, H | 1 |
| Kagawa, S | 1 |
| Kincses, ZT | 1 |
| Gulaj, E | 1 |
| Pawlak, K | 1 |
| Bien, B | 1 |
| Pawlak, D | 1 |
| Bonda, DJ | 1 |
| Mailankot, M | 1 |
| Stone, JG | 1 |
| Garrett, MR | 1 |
| Staniszewska, M | 1 |
| Castellani, RJ | 1 |
| Siedlak, SL | 1 |
| Zhu, X | 1 |
| Lee, HG | 1 |
| Perry, G | 1 |
| Nagaraj, RH | 1 |
| Smith, MA | 1 |
| Plangár, I | 1 |
| Tan, L | 2 |
| Yu, JT | 1 |
| Schwarz, MJ | 1 |
| Teipel, SJ | 1 |
| Buerger, K | 1 |
| Hampel, H | 1 |
| Noonan, CE | 1 |
| Hartai, Z | 1 |
| Juhász, A | 1 |
| Rimanóczy, A | 1 |
| Janáky, T | 1 |
| Donkó, T | 1 |
| Dux, L | 1 |
| Penke, B | 1 |
| Tóth, GK | 1 |
| Janka, Z | 1 |
| Kálmán, J | 1 |
| Ting, KK | 1 |
| Brew, B | 1 |
| Guillemin, G | 1 |
| Tohgi, H | 1 |
| Abe, T | 1 |
| Takahashi, S | 1 |
| Saheki, M | 1 |
| Kimura, M | 1 |
| Baran, H | 1 |
| Jellinger, K | 1 |
| Deecke, L | 1 |
| Ogawa, M | 1 |
| Widner, B | 2 |
| Walli, J | 2 |
| Tilz, GP | 2 |
| Demel, U | 2 |
| Beal, MF | 1 |
| Matson, WR | 1 |
| Storey, E | 1 |
| Milbury, P | 1 |
| Ryan, EA | 1 |
| Ogawa, T | 1 |
| Bird, ED | 1 |
| Pearson, SJ | 1 |
| Reynolds, GP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Influence of 12 Weeks Vitamin D Supplementation Combined With Physical Activity on Blood and Functional Parameters and Quality of Life in Parkinson's Disease Patients Treated With Deep Brain Stimulation[NCT04768023] | 50 participants (Actual) | Interventional | 2019-11-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
19 reviews available for kynurenine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Hypoxia and the Kynurenine Pathway: Implications and Therapeutic Prospects in Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Humans; Hypoxia; Kynurenine; Metabolic Networks and Pathways | 2021 |
Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Topics: Alzheimer Disease; Animals; Brain; Excitatory Amino Acid Antagonists; Humans; Huntington Disease; Ky | 2022 |
Kynurenine Pathway Metabolites as Biomarkers in Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Humans; Kynurenine; Quinolinic Acid | 2022 |
Kynurenine Metabolism and Alzheimer's Disease: The Potential Targets and Approaches.
Topics: Alzheimer Disease; HIV Infections; Humans; Kynurenine; Oxidative Stress; Tryptophan | 2022 |
The Tryptophan Catabolite or Kynurenine Pathway in Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Topics: Aged; Alzheimer Disease; Brain; Humans; Kynurenic Acid; Kynurenine; Tryptophan | 2022 |
Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis.
Topics: 3-Hydroxyanthranilic Acid; Adenosine; Alzheimer Disease; Humans; Huntington Disease; Hydroxyindoleac | 2022 |
Exploring the Etiological Links behind Neurodegenerative Diseases: Inflammatory Cytokines and Bioactive Kynurenines.
Topics: Alzheimer Disease; Anti-Inflammatory Agents; Biomarkers; Cytokines; Humans; Huntington Disease; Infl | 2020 |
Alzheimer's Disease: Recent Concepts on the Relation of Mitochondrial Disturbances, Excitotoxicity, Neuroinflammation, and Kynurenines.
Topics: Alzheimer Disease; Animals; Central Nervous System; Disease Models, Animal; Energy Metabolism; Gluta | 2018 |
Rollercoaster ride of kynurenines: steering the wheel towards neuroprotection in Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cognitive Dysfunction; Drug Development; Humans; Kynurenic Acid; Kynuren | 2018 |
Microbiota Alterations in Alzheimer's Disease: Involvement of the Kynurenine Pathway and Inflammation.
Topics: Alzheimer Disease; Animals; Gastrointestinal Microbiome; Humans; Inflammation; Kynurenine; Oxidative | 2019 |
The potential role of kynurenines in Alzheimer's disease: pathomechanism and therapeutic possibilities by influencing the glutamate receptors.
Topics: Alzheimer Disease; Animals; Glutamic Acid; Humans; Kynurenine; Neuroprotective Agents; Receptors, Gl | 2014 |
Alzheimer's disease, astrocytes and kynurenines.
Topics: Alzheimer Disease; Animals; Astrocytes; Brain; Glutamic Acid; Humans; Kynurenine | 2015 |
Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington's Disease.
Topics: Alzheimer Disease; Animals; Humans; Huntington Disease; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynure | 2015 |
The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection.
Topics: Alzheimer Disease; Animals; Brain; Brain Diseases; Brain Ischemia; Epilepsy; Humans; Huntington Dise | 2009 |
Kynurenines, neurodegeneration and Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Biosynthetic Pathways; Humans; Kynurenine; Molecular Struc | 2010 |
Targeting the kynurenine pathway-related alterations in Alzheimer's disease: a future therapeutic strategy.
Topics: Alzheimer Disease; Animals; Blood-Brain Barrier; Brain; Disease Models, Animal; Humans; Kynurenine; | 2011 |
The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Topics: Aging; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Enzyme Inhibitors; Humans; Hunting | 2012 |
Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Humans; Kynurenine; Quinolinic Acid; Tryptophan | 2002 |
The involvement of astrocytes and kynurenine pathway in Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Astrocytes; Brain Chemistry; Electrophysiology; Humans; Kynurenine; Nerv | 2007 |
2 trials available for kynurenine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Lowered Levels of Carbonyl Proteins after Vitamin B Supplementation in Patients with Mild Cognitive Impairment and Alzheimer's Disease.
Topics: Age Factors; Aged; Alzheimer Disease; Biomarkers; Cognitive Dysfunction; Dietary Supplements; Discri | 2016 |
Indoleamine concentrations in cerebrospinal fluid from patients with Alzheimer type and Binswanger type dementias before and after administration of citalopram, a synthetic serotonin uptake inhibitor.
Topics: Aged; Alzheimer Disease; Citalopram; Dementia, Vascular; Humans; Indoles; Kynurenine; Selective Sero | 1995 |
29 other studies available for kynurenine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Systemic perturbations of the kynurenine pathway precede progression to dementia independently of amyloid-β.
Topics: 3-Hydroxyanthranilic Acid; Alzheimer Disease; Amyloid beta-Peptides; Australia; Biomarkers; Cognitiv | 2022 |
The Involvement of Kynurenine Pathway in Neurodegenerative Diseases.
Topics: Alzheimer Disease; Cross-Sectional Studies; Humans; Kynurenine; Neurodegenerative Diseases; Parkinso | 2023 |
Tryptophan Metabolism and Neurodegeneration: Longitudinal Associations of Kynurenine Pathway Metabolites with Cognitive Performance and Plasma Alzheimer's Disease and Related Dementias Biomarkers in the Duke Physical Performance Across the LifeSpan Study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Biomarkers; Cognition; Humans; Kynurenine; Longevity; Tr | 2023 |
Divergent roles of astrocytic versus neuronal EAAT2 deficiency on cognition and overlap with aging and Alzheimer's molecular signatures.
Topics: Adult; Aged, 80 and over; Aging; Alzheimer Disease; Animals; Astrocytes; Cognition; Cognitive Dysfun | 2019 |
Plasma neurofilament light chain and amyloid-β are associated with the kynurenine pathway metabolites in preclinical Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Female; Humans; Kynur | 2019 |
Pyridine-2,3-dicarboxylate, quinolinic acid, induces 1N4R Tau amyloid aggregation in vitro: Another evidence for the detrimental effect of the inescapable endogenous neurotoxin.
Topics: Alzheimer Disease; Amyloid; Humans; Kynurenine; Neurotoxins; Protein Aggregates; Pyridines; Quinolin | 2020 |
Amyloid β neurotoxicity is IDO1-Kyn-AhR dependent and blocked by IDO1 inhibitor.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Basic Helix-Loop-Helix Transcription Factors; Dis | 2020 |
Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer's disease.
Topics: Alzheimer Disease; Biological Availability; Humans; Kynurenine; Serotonin; Tryptophan | 2021 |
Inflammation, negative affect, and amyloid burden in Alzheimer's disease: Insights from the kynurenine pathway.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cognitive Dysfunction; Humans; Inflammation; Kynurenine | 2021 |
Sex-specific alterations in NAD+ metabolism in 3xTg Alzheimer's disease mouse brain assessed by quantitative targeted LC-MS.
Topics: Alzheimer Disease; Animals; Chromatography, High Pressure Liquid; Encephalitis; Female; Humans; Kynu | 2021 |
Kynurenine Pathway Metabolites in Alzheimer's Disease.
Topics: 3-Hydroxyanthranilic Acid; Aged; Aged, 80 and over; Aging; Alzheimer Disease; Cognition Disorders; C | 2017 |
Proposed biochemistry of Parkinson's and Alzheimer's diseases.
Topics: Aldehydes; Alzheimer Disease; Aspartic Acid; Betaine; Brain; Disease Progression; Humans; Kynurenine | 2017 |
Alterations in serum kynurenine pathway metabolites in individuals with high neocortical amyloid-β load: A pilot study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Asymptomatic Diseases; Biomarkers | 2018 |
Correlation between plasma and CSF concentrations of kynurenine pathway metabolites in Alzheimer's disease and relationship to amyloid-β and tau.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Female; Humans; Kynurenine; Male; | 2019 |
Age- and disease-specific changes of the kynurenine pathway in Parkinson's and Alzheimer's disease.
Topics: Aged; Aging; Alzheimer Disease; Female; Humans; Kynurenine; Male; Middle Aged; Parkinson Disease | 2019 |
Immune activation in patients with Alzheimer's disease is associated with high serum phenylalanine concentrations.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Enzyme-Linked Immunosorbent Assay; | 2013 |
Expression of tryptophan 2,3-dioxygenase and production of kynurenine pathway metabolites in triple transgenic mice and human Alzheimer's disease brain.
Topics: 3-Hydroxyanthranilate 3,4-Dioxygenase; Aged; Aged, 80 and over; Alzheimer Disease; Animals; CA1 Regi | 2013 |
Proinflammatory cytokine interferon-gamma increases induction of indoleamine 2,3-dioxygenase in monocytic cells primed with amyloid beta peptide 1-42: implications for the pathogenesis of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Line, Tumor; Cells, Cultured; Enzyme Inducti | 2009 |
Kynurenine and its metabolites in Alzheimer's disease patients.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Chromatography, High Pressure Liquid; Female; Humans; Ky | 2010 |
Indoleamine 2,3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimer's disease.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Blotting, Western; Case-Control Studies; Hippocam | 2010 |
Increased 3-hydroxykynurenine serum concentrations differentiate Alzheimer's disease patients from controls.
Topics: Aged; Alzheimer Disease; Biomarkers; Blood-Brain Barrier; Brain Chemistry; Chromatography, High Pres | 2013 |
Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Astrocytes; Hippocampus; Humans; Immunohistochemistry; I | 2005 |
Decreased serum and red blood cell kynurenic acid levels in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Apolipoproteins E; Erythrocytes; Female; Genoty | 2007 |
Kynurenine metabolism in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Caudate Nucleus; Female; Humans; Kinetics; Kynure | 1999 |
[Biochemical, molecular genetic and ecogenetic studies of polymorphic arylamine N-acetyltransferase (NAT2) in the brain].
Topics: Acetylation; Alzheimer Disease; Animals; Arylamine N-Acetyltransferase; Brain; Humans; Kynurenine; P | 1999 |
Degradation of tryptophan in neurodegenerative disorders.
Topics: Alzheimer Disease; Biomarkers; Humans; Huntington Disease; Intellectual Disability; Interleukin-2; K | 1999 |
Tryptophan degradation and immune activation in Alzheimer's disease.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Brain; Female; Humans; Interferon-gamma; Kynureni | 2000 |
Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex.
Topics: Aged; Alzheimer Disease; Cerebral Cortex; Energy Metabolism; Free Radicals; Humans; Huntington Disea | 1992 |
Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease.
Topics: Aged; Alzheimer Disease; Brain Chemistry; Cerebral Cortex; Corpus Striatum; Female; Humans; Huntingt | 1992 |